Proanthocyanidins, particularly those found in grape seed extract, may help protect retinal ganglion cells against oxidative stress and mitochondrial alterations, which are important factors in glaucoma. Elevated intraocular pressure (IOP), a significant risk factor for glaucoma, can lead to retinal ganglion cell death. Some research suggests that proanthocyanidins may reduce eye pressure and improve visual function. [1, 2, 3, 4]
- Oxidative Stress and Glaucoma: In glaucoma, oxidative stress can damage retinal ganglion cells, contributing to their death. [1, 1, 2, 2, 5]
- Proanthocyanidin’s Protective Role: Proanthocyanidins, especially those from grape seed extract, have been shown to protect against oxidative stress and mitochondrial damage in retinal ganglion cells. [1, 1, 2, 2]
- Potential for IOP Reduction: Some studies suggest that proanthocyanidins may help reduce eye pressure (IOP) and improve visual function in glaucoma patients. [3, 3, 4, 4, 6, 7]
- Neuroprotection and Antioxidant Properties: Proanthocyanidins also exhibit neuroprotective and antioxidant properties, which may further benefit eye health. [3, 3, 4]
- Clinical Relevance: While promising, more research is needed to fully understand the role of proanthocyanidins in glaucoma treatment and prevention. [2, 2, 3, 3, 8, 9]
- Proanthocyanidins have been the subject of recent research, demonstrating antibactierial[9], antiviral[10,11], anticarcinogenic[12], anti-inflammatory[13,14], antiallergicvasodilatory[15,16], antiswelling[17] and neuroprotective activities[18,19,20,21]. More recently, Yang et al[22] verified that the grape seed extract was able to protect oxidative stressed-induced retinal ganglion cell damage. The in vitro studies on both Retinal Ganglion Cell-5 cell lines and retinal explants demonstrate that oligomeric proanthocyanidin can protect the oxidative stress injured retinal ganglion cells by inhibiting the apoptotic process, thus indicating a potential application of oligomeric proanthocyanidin in the clinical treatment of glaucoma and other optic diseases.1,
Generative AI is experimental.
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC4146041/
[2] https://pubmed.ncbi.nlm.nih.gov/33078305/
[3] https://www.grandridgeeyeclinic.com/glaucoma-supplements.html
[4] https://www.vision-and-eye-health.com/best-glaucoma-supplements/
[5] https://onlinelibrary.wiley.com/doi/full/10.1002/adbi.202300530
[6] https://pdfs.semanticscholar.org/b453/c4a89f5e603ba5d8655c33bf24eed83e4891.pdf
